|drug2340||Opt-out Recruitment Email Wiki||1.00|
|drug2933||Ruxolitinib Oral Tablet Wiki||0.71|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.08|
There is one clinical trial.
In order to safely and effectively reopen businesses and universities across the US, institutions will need to develop approaches to rapidly identify COVID-19 cases and manage their spread while balancing program effectiveness, feasibility, costs, and scalability. The investigators will evaluate the implementation of a COVID-19 screening program that coordinates several existing systems at the University of Pennsylvania including saliva-based viral testing and test different outreach strategies (opt-in vs opt-out) to improve program enrollment.
Description: The proportion of those invited that enroll in the studyMeasure: Proportion Enrolled Time: 4 weeks
Description: The average age of participants enrolled in the studyMeasure: Participant Age Time: 4 weeks
Description: The proportion of females enrolled in the studyMeasure: Participant Sex Time: 4 weeks
Description: The proportion of enrolled participants belonging to specified categories of race (e.g., Alaska Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White or Caucasian) and ethnicity (i.e., Hispanic or Latino, Non-Hispanic or Latino)Measure: Participant Race/Ethnicity Time: 4 weeks
Description: The proportion of enrolled participants belonging to specified categories of income (e.g., Less than $10000, $10000 to $19999, $20000 to $29999, $150000 or more)Measure: Participant Income Time: 4 weeks
Description: The proportion of enrolled participants belonging to specified categories of education (e.g., less than high school, some high school, high school grad, college: 4 year degree, post-college education)Measure: Participant Education Time: 4 weeks
Description: The proportion of enrolled participants that submit a saliva sampleMeasure: Test Completion Time: 8 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports